Freeport, The Bahamas (PRWEB) October 03, 2013 Okyanos Heart Institute, whose mission is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy, has announced that they will be hosting a free educational seminar for the business community and all other interested individuals on Tuesday, October 22nd from 5:30 6:30 pm in the Coral Reef Room of the Pelican Bay Hotel in Lucaya, Grand Bahama Island. Registration is requested to attend as seating is limited. Howard Walpole, M.D., M.B.A., F.A.C.C., F.S.C.A.I. and chief medical officer and interventional cardiologist for Okyanos Heart Institute will provide an overview of stem cell therapy for heart disease, the source of stem cells, how it is intended to work, and the protocol that will be used by the cath lab for patients once the facility is open in February, 2014. Erika Mangrum, SVP of Communications for the company, will provide an overview of what services will be needed by small businesses on the island, such as janitorial, hospital grade laundry, transportation, catering and more. A preliminary list of jobs that Okyanos Heart Institute will need to fill towards the end of the … Continue reading →

Molly 30 Day Post Stem Cell Treatment # 1 of 3 Molly 30 Day Post Stem Cell Treatment # 1 of 3. By: Thomas Beall … Continue reading →

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 8 hours ago In a paper in Cell Stem Cell, a team led by researchers in the Boston Children's Hospital's Stem Cell Transplantation Program reports a new approach for turning induced pluripotent stem cells (iPSCs) into hematopoietic stem and progenitor cells for in vivo disease modeling. With this strategywhich they call re-specificationthe team, including Sergei Doulatov, PhD, and George Daley, MD, PhD, of Boston Children's, may have overcome technical barriers to generating blood disease-specific animal models from the thousands of iPSC cell lines now sitting in laboratory freezers around the world. The main advantage of the technique lies in the raw material. The research team started with iPSCs that had already been directed to grow into myeloid progenitors, which are more closely related to the desired blood progenitors than skin or other fully differentiated cell types commonly used in stem cell experiments. The researchers then used a select set of transcription factors to turn back the molecular clock just a little on these committed myeloid cells, turning them into blood progenitors that readily … Continue reading →

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? … Continue reading →

Though the Food and Drug Administration remains closed due to the federal government shutdown, researchers at the University are pushing forward the development of stem-cell therapies, with the hope of improving the quality of life for individuals with life-threatening disabilities. Researchers at University Hospital and the A. Alfred Taubman Medical Research Institute are exploring the use of stem cells in the treatment of amyotrophic lateral sclerosis also known as Lou Gerhigs disease, a neurodegenerative condition that causes cell death in spinal cord neurons that control movement. Patients with ALS suffer from loss of muscle control and often die of respiratory failure. Neurology Prof. Eva Feldman presented recent results from her research at an event Wednesday evening at the Taubman Institutes Kahn Auditorium for an audience of about 40 students and faculty. Feldman discussed the completion of Phase I trials of the new stem-cell therapy and her plans for Phase II. While Phase I trials typically test the safety of a treatment in human patients, Phase II tests the treatments efficacy. Feldmans research team received approval for Phase II of their research in May and has since begun tests. Shortly before the event Wednesday afternoon, a third patient enrolled in the … Continue reading →

Public release date: 2-Oct-2013 [ | E-mail | Share ] Contact: Tim Hawkins timothy.hawkins@spectrumhealth.org 616-443-0361 Spectrum Health GRAND RAPIDS, Mich., October 2, 2013 A recently published study by researchers from Spectrum Health and Henry Ford Hospital suggests that surgery may be an effective treatment for epilepsy in older patients, a finding that runs counter to conventional treatment methods. "Traditionally, there has been a tendency to exclude older patients from surgery for fear of increased risk of medical or surgical complications," said Spectrum Health Medical Group neurosurgeon Sanjay Patra, MD, lead author of the study. "This study provides evidence that surgery may instead be a viable and effective treatment option." The study, recently published online in the British Journal of Neurosurgery, uses a retrospective institutional archival review of 122 Henry Ford Hospital patients with medically refractory partial epilepsy. Medically refractory seizures are those that do not respond successfully to drug treatment. Partial epilepsy refers to a type of seizure that originates and remains in a limited area of the brain, such as the temporal lobe. Researchers compared surgical outcomes of a group of patients aged 50 years and older with those of a younger group of patients. The median follow-up time … Continue reading →

Tokyo, Oct 3, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has received approval from the European Commission (EC) on the license extension application submitted by its U.K. subsidiary Eisai Ltd. regarding the use of antiepileptic agent Zonegran (zonisamide) in the treatment of pediatric patients. The approval extends the use of adjunctive Zonegran in the treatment of partial seizures (with or without secondary generalization) by changing the approved age range from adults aged 18 years and above to now also include pediatric patients aged 6 years and above. Zonegran is an antiepileptic drug (AED) originally created by Dainippon Pharmaceutical Co., Ltd. (currently Dainippon Sumitomo Pharma Co., Ltd.), for which Eisai has been pursuing development of the agent in Europe. Zonegran was first approved in March 2005 as an adjunctive therapy for the treatment of partial-onset seizures (with or without secondary generalization) in adults with epilepsy and received additional approval in June 2012 as a monotherapy for partial-onset seizures in adults with newly diagnosed epilepsy. The agent is currently marketed in Europe by Eisai's subsidiaries. The data used in the application was from a double-blind, randomized, multicenter, placebo-controlled, pivotal … Continue reading →

The European Commission (EC) has approved the paediatric licence variation of Zonegran (zonisamide), a novel anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AED.[1] Zonisamide is now indicated as an adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adolescents and children aged six years and above in addition to its existing license in adult patients.[1] Epilepsy is a common condition in children and adolescents, affecting around 10.5 million worldwide, with nearly one million living in Europe.[2] However, only two thirds of these youngsters will achieve seizure control and many will require additional AEDs to improve seizure control.[3] Epilepsy in children often presents major challenges such as developmental and behavioural problems resulting in educational underachievement and a lack of self-esteem. These issues, which are frequently manifested in an attention deficit disorder, withdrawal, anxiety or depression, have a negative impact on both the child and their family.[4] "It is pleasingthat Zonegran has now been licensed to be prescribed for children, as new options for young people with epilepsy are needed desperately," said Professor Helen Cross, Great Ormond Street Hospital and Young Epilepsy. "Epilepsyaffects all aspects of children and … Continue reading →